other material
confidence high
sentiment positive
materiality 0.55
Lixte reports new pre-clinical data on LB-100 activation and potential biomarker for patient response
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Enzyme discovered that converts LB-100 to active metabolite endothall, published in BioXriv and Int'l J. Pharmaceutics.
- Findings open potential biomarker strategy to identify patients most likely to respond to LB-100.
- LB-100 also spontaneously converts via slow hydrolysis; enzymatic conversion inside cell expedites activation.
- Clinical trials for LB-100 in ovarian and colorectal cancer continue; CEO says data will help optimize patient selection.